GlaxoSmithkline Consumer Healthcare (SBCH) has posted a strong 27% topline growth during the June quarter. It seems that the company's relaunch strategy for both Horlicks and Boost seems to have rubbed off on the performance. It may also be an indication that the inventory correction undertaken by the company last year is now over. There is a minor difference between our revenue growth and the reported growth due to change in numbers of previous quarter figures.
Operating Profit (EBDIT)
Operating Profit Margin (%)
Profit before Tax
Profit after Tax/(Loss)
Net profit margin (%)
No. of Shares
Diluted Earnings per share*
One must remember that the June quarter last year was exceptionally bad for the company. Topline during that period had declined by a huge 26%. If we see from this angle, then the company has only managed to recoup lost ground. But one thing is for sure. The result posted by SBCH this quarter are likely to pep up investor interest towards this malted beverage major once again.
2002 was one of the worst years for the company, wherein it reported a 12.5% dip in topline and nearly 33% decline in profits. Even in the March quarter this year, GSK Consumer had reported a marginal dip in the topline. The strong growth witnessed this quarter is a sign that the company has managed to address topline concerns successfully. This could have been led by new product introductions in an effort to reposition its ageing brands.
Expenses as a % of sales
Patent and trademark
Def. Rev. exps.
At the operating level, expenses grew almost neck to neck with the topline. Consequently, GSK Consumer did not see significant benefits on the operating margins front. Higher raw material and other expense were the key contributors to the expense growth. Depreciation provisioning also increased on account of the new 26,000 tonne malted food plant at Sonepat. All this resulted in the company declaring almost similar net profits as in the corresponding quarter last year. On a consolidated half year basis, SBCH has clocked an encouraging 11% topline growth, but a 22% bottomline dip. The company has declared an interim dividend of Rs 3.3 per share.
At Rs 266, the stock trades at 15x annualised 1HFY04 earnings with market cap to sales at 1.6x. As said earlier, the strong growth in June quarter topline is likely to perk investor interest towards the stock. We are still awaiting the management's take on the topline growth and whether it is a sustainable trend. But overall, we are enthused by prospects of a turnaround story.
GSK Consumer Healthcare declared results for the quarter ended September 2016. The revenues dropped by 1.3% during the quarter as compared to a year ago; while the profits declined by 16.6% YoY during the quarter.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407